Glycine betaine and its use

• US 7,608,640 B2
• Filed: 08/04/2003
• Issued: 10/27/2009
• Est. Priority Date: 03/02/1999
• Status: Expired due to Fees

• Current Assignee: Jallal Messadek
• Original Assignee: Jallal Messadek
• Inventors: Messadek, Jallal
• Primary Examiner(s): Padmanabhan; Sreeni
• Assistant Examiner(s): Betton; Timothy E
• Application Number:
  US10/635,048
• Publication Number:
  US 20040033223A1
• Time in Patent Office: 2,276 Days
• Field of Search: 514/165
• US Class Current: 514/561
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

Claims

1. A controlled release pharmaceutical system suitable for delivering after administration in a time-controlled manner to the bloodstream of a mammal comprising an effective amount of an active compound selected from the group consisting of a compound of the formula (CH₃)₃N⁺(CH₂)_nCOO⁻

, with n equal to 1, pharmaceutically acceptable salts thereof, and mixtures thereof.

2. The system of claim 1, said system being selected from the group consisting of oral control led release preparations, oral controlled release devices, transdermal controlled release preparations, transdermal controlled release devices, and combinations thereof.

3. The system of claim 1 wherein said system comprises at least one electronic element selected from the group consisting of an electronic device and chip, said at least one element operable for controlling at least the releasing of the active compound.

4. The system of claim 1, said system controlling delivery of said compound for at least about 120 minutes.

5. A controlled release pharmaceutical system for achieving a goal selected from the group consisting of treating a condition, reducing the incidence of a condition, and reducing the severity of a condition, whereby said condition is selected from the group consisting of blood flow disturbances, thrombosis, thromboembolic disorders, and combinations thereof, said system being adapted for releasing in a time controlled manner for at least 120 minutes, after administration, a therapeutically effective amount of an active compound selected from the group consisting of a compound of the formula (CH₃)₃N⁺(CH₂)_nCOO⁻

, with n equal to 1, pharmaceutically acceptable salts of said compound, and mixtures thereof.

6. The system of claim 5, said system being an oral controlled release pharmaceutical system.

7. The system of claim 5 wherein said system comprises at least one electronic element selected from the group consisting of an electronic device and chip, said element being operable for controlling the release of the active compound.

8. The system of claim 5, wherein the system is adapted for controlling the release of said active compound for at least for 180 minutes.

9. The system of claim 5, wherein the system is adapted for controlling the release of said active compound for at least for 240 minutes.

10. The system of claim 5, wherein the system is adapted for controlling the release of said active compound for at least for 360 minutes.

11. A controlled release pharmaceutical system tor releasing an effective therapeutic amount of a compound selected from the group consisting of a compound of the formula (CH₃)₃N⁺(CH₂)_nCOO⁻

, with n equal to 1, pharmaceutically acceptable salts thereof, and mixtures thereof, wherein said system is adapted for controlling for at least 120 minutes the release of an effective amount of a compound of glycine betaine, pharmaceutically acceptable salts thereof, and mixtures thereof.

12. The system of claim 11, in which the system is adapted for controlling at least for 180 minutes the release of an effective amount of a compound selected from the group consisting of a compound of formula (CH3)3N+(CH2)n COO⁻

with n being an integer of 1, pharmaceutically acceptable salts thereof, and mixtures thereof.

13. The system of claim 11, in which the system is adapted for controlling the release of an effective amount of a compound selected from the group consisting of a compound of formula (CH3)3N+(CH2)n COO⁻

with n being an integer of 1, pharmaceutically acceptable salts thereof, and mixtures thereof for a time period of from about 240 minutes to 2160 minutes.

14. The system of claim 11 wherein said system comprises at least one electronic element selected from the group consisting of an electronic device and chip, said element being operable for controlling the release of the active compound.

15. A controlled release pharmaceutical system for achieving a goal selected from the group consisting of treating a condition, reducing the incidence of a condition, and reducing the severity of a condition, whereby said condition is selected from the group consisting of blood flaw disturbances, thrombosis, thromboembolic disorders, and combinations thereof, said system being adapted for releasing in a time controlled manner for at least 2160 minutes, after administration, a therapeutically effective amount at an active compound selected from the group consisting of a compound of the formula (CH₃)₃N⁺(CH₂)_nCOO⁻

, with n equal to 1, pharmaceutically acceptable salts thereof, and mixtures thereof.